336
A role for Janus cyclohexyl ring motifs in medicinal chemistry. Incorporation into G-Quadruplex ligands and anti-Trypanosoma brucei activity
Josephine M. Stewart, Mario Kehler,Vytautas Kuodis, Gary N. Parkinson, Wenqian Chen, Terry K. Smith Zoë A. E. Waller and David O’Hagan.
ChemBioChem, 2026, in press
335
Fluorine-Induced Elimination Drives Mechanism-Based Inactivation of Isocitrate Lyase
Kolambapatabandige G. S. Fernando, Yohann J. G. Renault, Rachel Molino, David O’Hagan, Andrew S. Murkin.
Biochemistry, 2026, 65, (17): 2747–2755.
doi.org/10.1021/acs.biochem.6c00478
334
Incorporation and properties of the tris-fluoromethylated motif into heterocycles, amino acids and analogues of elexacaftor and tezacaftor
Josephine M. Stewart, Bruno A. Piscelli, David B. Cordes, Rodrigo A. Cormanich, David O’Hagan
Chem. Sci., 2026; 17 (33): 15938–15946
333
A2A Adenosine Receptor Agonists With Last-Step Enzymatic 18F-Labelling Potential (Fluorinase) for Positron Emission Tomography (PET)
Nicolas Charalambous, Carina Schleidt, Rongfang Liu, Laura H. Heitman, Sergio Dall’Angelo, David O’Hagan, Phillip T. Lowe
Eur. J. Org. Chem. 2026; 29:e202501125
doi.org/10.1002/ejoc.202501125
332
On the Nature of Improper Hydrogen Bonding in RCH2F and RCHF2 Motifs.
Bruno A. Piscelli, Michael Bühl, Rodrigo A. Cormanich and David O’Hagan
Angew. Chem. Int. Ed. 2025, 65, e18500
doi.org/10.1002/anie.202518500